Clinical Neuropharmacology最新文献_第2页

Clinical Response to IM Olanzapine in Akinetic Mutism: Case Report. IM奥氮平治疗不动性缄默症的临床反应：1例报告。

IF 0.8 4区医学

Clinical Neuropharmacology Pub Date : 2025-05-01 DOI: 10.1097/WNF.0000000000000634

Alexandre Yacques, Lashonda Payne, Brendan T Carroll

引用次数: 0

The Impact of Preoperative Low-Dose Esketamine and Dexmedetomidine Nasal Administration on the Emergence Delirium in Children Undergoing Fiber Bronchoscopy: A Prospective Randomized Controlled Trial. 术前低剂量艾氯胺酮和右美托咪定鼻给药对纤维支气管镜检查儿童出现性谵妄的影响：一项前瞻性随机对照试验。

IF 0.8 4区医学

Clinical Neuropharmacology Pub Date : 2025-05-01 Epub Date: 2025-04-07 DOI: 10.1097/WNF.0000000000000637

Wei Xie, Le Wang, Zhe Peng, Rong Zhang, Zhi Fang Dong, Ying Huang, Zi Hao Wan, Li Wang

{"title":"The Impact of Preoperative Low-Dose Esketamine and Dexmedetomidine Nasal Administration on the Emergence Delirium in Children Undergoing Fiber Bronchoscopy: A Prospective Randomized Controlled Trial.","authors":"Wei Xie, Le Wang, Zhe Peng, Rong Zhang, Zhi Fang Dong, Ying Huang, Zi Hao Wan, Li Wang","doi":"10.1097/WNF.0000000000000637","DOIUrl":"10.1097/WNF.0000000000000637","url":null,"abstract":"Objective: This study aimed to investigate the effects of preoperative low-dose esketamine and dexmedetomidine nasal administration on the incidence of postoperative emergence delirium in children undergoing fiber bronchoscopy.Methods: A total of 129 patients, of any gender, aged 1 to 6 years, with ASA grades I and II, who were scheduled for fiber bronchoscopy, were randomly divided into three groups (n = 43) using a random number table method: 1.0 mg/kg of esketamine, 1.0 μg/kg of dexmedetomidine, and an equal volume of normal saline (group control). The respective dose of the drug or normal saline was rapidly instilled through both nostrils using a 1-mL syringe. The primary outcome measure was the incidence of emergence delirium. The secondary outcome measures included postoperative pain intensity, time to awaken and open eyes in the postanesthesia care unit, incidence of postoperative adverse behavior, hemodynamics, and duration of stay in the postanesthesia care unit.Results: A total of 126 patients completed the study, and compared with the group control (48.78%), the 1.0 mg/kg esketamine (7.14%) and 1.0 μg/kg dexmedetomidine (18.6%) had a lower incidence of postoperative emergence delirium ( P < 0.01), as well as lower postoperative pain intensity ( P < 0.01). However, compared with the group control, the 1.0 μg/kg dexmedetomidine had a prolonged time to awaken and open eyes in the postanesthesia care unit ( P < 0.05). The duration of hemodynamics, oral secretion volume, and stay in the postanesthesia care unit were similar among the three groups.Conclusions: The findings suggest that low-dose esketamine and dexmedetomidine can reduce the incidence of emergence delirium.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"97-103"},"PeriodicalIF":0.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dextromethorphan as an Opioid-Sparing Analgesic in Postoperative Pain. 右美沙芬作为阿片类镇痛药在术后疼痛中的应用。

IF 0.8 4区医学

Clinical Neuropharmacology Pub Date : 2025-04-08 DOI: 10.1097/WNF.0000000000000638

Ravindrasingh Rajput, Karim Al Harakeh, Gustavo Figueras, Ashveen Mahi, Manahil Minhas, Diana Sobolevskaia, S Durga Prasad, Amruta Rajput

{"title":"Dextromethorphan as an Opioid-Sparing Analgesic in Postoperative Pain.","authors":"Ravindrasingh Rajput, Karim Al Harakeh, Gustavo Figueras, Ashveen Mahi, Manahil Minhas, Diana Sobolevskaia, S Durga Prasad, Amruta Rajput","doi":"10.1097/WNF.0000000000000638","DOIUrl":"https://doi.org/10.1097/WNF.0000000000000638","url":null,"abstract":"Abstract: Dextromethorphan, traditionally known as a cough suppressant, is emerging as a potent opioid-sparing analgesic in perioperative pain management. This review explores dextromethorphan's multifaceted role in reducing postoperative pain and minimizing opioid consumption, thus optimizing patient recovery and mitigating adverse effects associated with conventional analgesics. Dextromethorphan operates through diverse mechanisms, including N-methyl-d-aspartate receptor antagonism, sigma-1 receptor agonism, and the inhibition of serotonin and norepinephrine reuptake, offering a broad therapeutic window across various types of pain, notably perioperative and neuropathic pain. Clinical trials highlight dextromethorphan's efficacy in lowering pain scores and reducing postoperative opioid requirements, aligning with multimodal analgesia principles, and enhancing patient outcomes. For instance, studies have demonstrated significant reductions in pain and opioid use postsurgery, without compromising safety or recovery milestones. However, dextromethorphan's effectiveness varies, with limited impact in conditions such as postherpetic neuralgia, underscoring the need for tailored pain management strategies. Incorporating dextromethorphan into perioperative protocols demonstrates its potential in reducing opioid reliance, a crucial aspect amid the opioid crisis. This review concludes that dextromethorphan, while requiring further research to fully elucidate its role in pain syndromes and establish comprehensive dosing guidelines, represents a promising adjunct in effective multimodal analgesia, marking a step forward in improving postoperative care and patient satisfaction.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":""},"PeriodicalIF":0.8,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative Analysis of the Efficacy of Esomeprazole and Ilaprazole in Patients With Neurological Disorders Using the Gastroesophageal Reflux Disease Questionnaire. 用胃食管反流病问卷对比分析埃索美拉唑与伊拉唑治疗神经系统疾病的疗效。

IF 0.8 4区医学

Clinical Neuropharmacology Pub Date : 2025-03-01 Epub Date: 2025-02-17 DOI: 10.1097/WNF.0000000000000623

Chae Hyun Kim, Ye Ryung Kim, Hyun Goo Kang

{"title":"Comparative Analysis of the Efficacy of Esomeprazole and Ilaprazole in Patients With Neurological Disorders Using the Gastroesophageal Reflux Disease Questionnaire.","authors":"Chae Hyun Kim, Ye Ryung Kim, Hyun Goo Kang","doi":"10.1097/WNF.0000000000000623","DOIUrl":"10.1097/WNF.0000000000000623","url":null,"abstract":"Objectives: Proton pump inhibitors (PPIs) are widely used to reduce gastric acid levels and are often prescribed with antiplatelet agents in patients with stroke. However, the interactions and differences among various PPIs remain unclear. Therefore, we aimed to compare the differences between esomeprazole and ilaprazole in patients with and without stroke. We also compared the effects of aspirin use in the ilaprazole group.Methods: We retrospectively analyzed 580 patients with neurological disorders who responded to the Gastroesophageal Reflux Disease Questionnaire at a tertiary hospital between October 2020 and December 2023. Comparative and subgroup analyses were performed using the chi-squared test, Fisher's exact test, and t tests.Results: In the overall patient cohort, patients using esomeprazole had lower rates of dyslipidemia and lower white blood cell, hemoglobin, triglyceride, and low-density lipoprotein cholesterol levels, compared to ilaprazole users. However, among patients with stroke, esomeprazole users had higher rates of atrial fibrillation and lower triglyceride, hemoglobin, and uric acid levels, compared to ilaprazole users. In the ilaprazole group, nonaspirin users were younger and had fewer stroke episodes and higher total cholesterol levels, compared to aspirin users. Furthermore, patients using antiplatelet and PPI therapies and antacids had lower hemoglobin levels, compared to antacid nonusers.Conclusions: Significant differences existed between esomeprazole and ilaprazole users and among ilaprazole users based on aspirin use. Therefore, careful monitoring of PPI use with antiplatelet agents and antacids is recommended in patients with neurological disorders. However, further research is needed to understand these differences and their clinical impact.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"29-38"},"PeriodicalIF":0.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143540442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of Attention-Deficit/Hyperactivity Disorder in Outpatients With a History of Disordered Eating Symptoms. 有进食障碍病史的门诊患者注意缺陷/多动障碍的治疗

IF 0.8 4区医学

Clinical Neuropharmacology Pub Date : 2025-03-01 Epub Date: 2025-02-17 DOI: 10.1097/WNF.0000000000000626

Robert P Wilfahrt, Abigail L Matthews

{"title":"Treatment of Attention-Deficit/Hyperactivity Disorder in Outpatients With a History of Disordered Eating Symptoms.","authors":"Robert P Wilfahrt, Abigail L Matthews","doi":"10.1097/WNF.0000000000000626","DOIUrl":"10.1097/WNF.0000000000000626","url":null,"abstract":"Objective: The aim of the study was to assess the characteristics and outcomes of adults with attention-deficit/hyperactivity disorder (ADHD) and a previous history of restrictive eating disorder symptoms.Method: We retrospectively reviewed the health records of patients with ADHD and a history of disordered eating who were treated at our institution with medications that have potential anorexiant properties from October 1, 2022, through March 31, 2024.Results: We initially identified 159 patients who were referred to an ADHD program at our institution during the study period. Of 72 patients who met criteria for an ADHD diagnosis, 18 had SCOFF questionnaire scores of 2 or higher, which suggests symptoms of a restrictive eating disorder. Of these 18 patients, 3 had a previous diagnosis of an eating disorder documented in their health records. Each patient was treated with medications chosen to manage their reported ADHD symptoms, regardless of eating disorder concerns. All patients had improvements in ADHD symptoms without reporting adverse effects on disordered eating behaviors. Body weight and body mass index values did not significantly change after treatment with atomoxetine, dextroamphetamine/amphetamine, or methylphenidate (all P ≥ 0.14).Conclusions: Our findings are consistent with those of previous reports and suggest that ADHD treatment, including treatment with stimulant medications, is safe and tolerable for patients with a history of restrictive eating disorder symptoms.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"39-42"},"PeriodicalIF":0.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143540444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety and Outcomes of Valproic Acid in Subarachnoid Hemorrhage Patients: A Retrospective Study. 丙戊酸治疗蛛网膜下腔出血患者的安全性和预后：一项回顾性研究。

IF 0.8 4区医学

Clinical Neuropharmacology Pub Date : 2025-03-01 Epub Date: 2025-02-19 DOI: 10.1097/WNF.0000000000000627

Matthew J Cobler-Lichter, Kushak Suchdev, Hayley Tatro, Ava Cascone, Joanna Yang, Janice Weinberg, Mohamad K Abdalkader, Hormuzdiyar H Dasenbrock, Charlene J Ong, Anna Cervantes-Arslanian, David Greer, Thanh N Nguyen, Ali Daneshmand, David Y Chung

{"title":"Safety and Outcomes of Valproic Acid in Subarachnoid Hemorrhage Patients: A Retrospective Study.","authors":"Matthew J Cobler-Lichter, Kushak Suchdev, Hayley Tatro, Ava Cascone, Joanna Yang, Janice Weinberg, Mohamad K Abdalkader, Hormuzdiyar H Dasenbrock, Charlene J Ong, Anna Cervantes-Arslanian, David Greer, Thanh N Nguyen, Ali Daneshmand, David Y Chung","doi":"10.1097/WNF.0000000000000627","DOIUrl":"10.1097/WNF.0000000000000627","url":null,"abstract":"Objectives: Animal studies have suggested that valproic acid (VPA) is neuroprotective in aneurysmal subarachnoid hemorrhage (SAH). However, the effect of VPA on SAH outcomes in humans has not been investigated.Methods: We conducted a retrospective analysis of 123 patients with nontraumatic SAH. Eighty-seven patients had an aneurysmal source and 36 patients had no culprit lesion identified. We used stepwise logistic regression to determine the association between VPA and delayed cerebral ischemia (DCI), radiographic vasospasm, and discharge modified Rankin Scale (mRS) score >3.Results: All 18 patients who received VPA underwent coil embolization of their aneurysm. VPA use did not have a significant association with DCI on adjusted analysis (odds ratio [OR] = 1.07, 95% confidence interval [CI]: 0.20-5.80). The association between VPA use and vasospasm was OR = 0.64 (0.19-1.98) and discharge mRS > 3 was OR = 0.45 (0.10-1.64). Increased age (OR = 1.04, 1.01-1.07) and Hunt and Hess grade >3 (OR = 14.5, 4.31-48.6) were associated with poor discharge outcome (mRS > 3). Younger age (OR = 0.96, 0.93-0.99), modified Fisher Scale (mFS) score = 4 (OR = 4.14, 1.81-9.45), and Hunt and Hess grade >3 (OR = 2.92, 1.11-7.69) were all associated with development of radiographic vasospasm. There were no complications associated with VPA administration.Conclusions: We did not observe an association between VPA and the rate of DCI. We found that VPA use was safe in SAH patients who have undergone endovascular treatment of their aneurysm.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":" ","pages":"43-50"},"PeriodicalIF":0.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143540443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neuroprotective Effects of Metformin in Stroke Patients: A Systematic Review and Meta-analysis of Cohort Studies. 二甲双胍对脑卒中患者的神经保护作用：队列研究的系统回顾和荟萃分析。

IF 0.8 4区医学

Clinical Neuropharmacology Pub Date : 2025-03-01 DOI: 10.1097/WNF.0000000000000625

Mohammad Mohammadi, Sadaf Salehi, Adrina Habibzadeh, Aynaz Mohammadi, Zahra Mirzaasgari

{"title":"Neuroprotective Effects of Metformin in Stroke Patients: A Systematic Review and Meta-analysis of Cohort Studies.","authors":"Mohammad Mohammadi, Sadaf Salehi, Adrina Habibzadeh, Aynaz Mohammadi, Zahra Mirzaasgari","doi":"10.1097/WNF.0000000000000625","DOIUrl":"10.1097/WNF.0000000000000625","url":null,"abstract":"Objectives: People with diabetes are 1.5 times more likely to experience stroke than those without diabetes, underlining the urgent need to address this issue. Metformin is often the initial medication chosen to manage diabetes mellitus (DM). The purpose of our systematic review and meta-analysis is to explore the potential neuroprotective effects of metformin in individuals who have received it prior to stroke.Method: Our study encompassed cohort studies that drew a comparison between the severity and diverse outcomes of stroke among individuals with DM who were administered metformin prior to the stroke event and those with DM who did not receive the treatment.Results: Ten studies met the eligibility criteria. Prestroke metformin use was associated with a significantly lower National Institutes of Health Stroke Scale score (mean difference = -1.29, 95% confidence interval: -2.11 to -0.47) in ischemic stroke. Metformin pretreatment in ischemic stroke was associated with increased odds of favorable outcome (mRS < 2) at 90 days (odds ratio [OR] = 1.45, 95% confidence interval [CI]: 1.06 to 1.99), but it was not significant at discharge. Metformin was found to be associated with reduced mortality (OR = 0.52, 95% CI: 0.42 to 0.64) in ischemic stroke. In hemorrhagic stroke, the results showed a significantly lower intracranial hemorrhage volume in prestroke metformin use (mean difference = -4.77, 95% CI: -6.56 to -2.98).Conclusions: We found that prestroke metformin use in diabetic patients yielded neuroprotective effects. In ischemic strokes, metformin reduces stroke severity and 90-day mortality; it also improves 90-day functional outcomes. In hemorrhagic strokes, prestroke metformin use can also cause less intracranial hemorrhage volume. Further clinical trials are needed to confirm its efficacy and verify its benefits in stroke management.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":"48 2","pages":"51-59"},"PeriodicalIF":0.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143613774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trait Impulsivity Predicts Treatment Response in Gambling Disorder. 特质冲动性预测赌博障碍的治疗反应。

IF 0.8 4区医学

Clinical Neuropharmacology Pub Date : 2025-03-01 Epub Date: 2025-01-31 DOI: 10.1097/WNF.0000000000000622

Samuel R Chamberlain, Konstantinos Ioannidis, Jon E Grant

引用次数: 0

A Case of Post-Acute Severe Acute Respiratory Syndrome Coronavirus 2-Induced Focal Nonconvulsive Status Epilepticus With Impairment of Consciousness Initially Diagnosed as Anxiety. 急性后严重急性呼吸综合征冠状病毒2型致局灶性非惊厥性癫痫持续状态伴意识损害1例初步诊断为焦虑

IF 0.8 4区医学

Clinical Neuropharmacology Pub Date : 2025-03-01 Epub Date: 2025-02-05 DOI: 10.1097/WNF.0000000000000621

Megan-Jayne Ralston, Faith Reed, Alim Osman

引用次数: 0

Evaluating Delta-8-THC-Induced Psychosis: A Systematic Review. 评估δ -8-四氢大麻酚诱导的精神病：一项系统综述。

IF 0.8 4区医学

Clinical Neuropharmacology Pub Date : 2025-01-01 DOI: 10.1097/WNF.0000000000000619

Megan Jayne Ralston, Alim Osman

{"title":"Evaluating Delta-8-THC-Induced Psychosis: A Systematic Review.","authors":"Megan Jayne Ralston, Alim Osman","doi":"10.1097/WNF.0000000000000619","DOIUrl":"10.1097/WNF.0000000000000619","url":null,"abstract":"Objectives: This study reviews literature on the psychiatric effects of delta-8-THC, particularly psychosis and severe mental health outcomes, to highlight the need for further research and regulation.Background: Marijuana, the most widely used illicit drug in the United States, sees increasing use due to legalization. Although moderate use is generally safe, adverse effects can occur, especially in those with preexisting conditions. Delta-9-THC is known for its psychoactive effects and potential to induce psychosis. Delta-8-THC, another cannabinoid, is gaining popularity and has been linked to severe adverse events but remains under-researched.Methods: A comprehensive search of PubMed and Web of Science followed PRISMA guidelines to identify studies and case reports on delta-8-THC and psychosis. Articles on delta-9-THC or other cannabinoids were excluded. Relevant studies were screened, and duplicates removed. The included studies were evaluated using the Critical Appraisal Skills Programme Checklist for Case Reports.Results: The search identified 201 studies, with 12 meeting the inclusion criteria for full-text analysis. Six case reports, involving 9 patients, were reviewed. Most patients were male and in their 20s, with varied psychiatric histories, including no prior psychiatric history, schizophrenia, posttraumatic stress disorder, and generalized anxiety disorder. Reported symptoms included psychosis, mood lability, and cannabinoid hyperemesis syndrome. Treatments varied, with different clinical outcomes.Conclusions: Delta-8-THC poses significant psychiatric risks despite being less intoxicating than delta-9-THC. The lack of Food and Drug Administration regulation and the availability of delta-8-THC products heighten these risks. More rigorous studies are needed to understand delta-8-THC's impact on mental health and inform regulatory actions.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":"48 1","pages":"20-23"},"PeriodicalIF":0.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143055978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0